読み込み中
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
前日終値
$143.73
+$3.82 · +2.73%
日中の時刻はETです。市場データは遅延する場合があります。
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
日中レンジ
現在 $143.73
52週レンジ
現在 $143.73
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
2
著しい割高
センチメント
59
まちまち
リスク
46
やや高いリスク
モメンタム
80
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
日中レンジ
現在 $143.73
52週レンジ
現在 $143.73
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 4601.6万 USD | 4.34億 USD | 6000万 USD | 2658.1万 USD | 2735.7万 USD |
| 売上原価 | 122.5万 USD | — | — | — | — |
| 粗利益 | 4479.1万 USD | 4.34億 USD | 6000万 USD | 2658.1万 USD | 2735.7万 USD |
| 研究開発 | 1.59億 USD | 1.38億 USD | 1.2億 USD | 1.26億 USD | 1.26億 USD |
| 販売・一般管理 | 4485.3万 USD | 4346.2万 USD | 3349.1万 USD | 3173.9万 USD | 2719.6万 USD |
| 営業費用 | 2.03億 USD | 1.82億 USD | 1.54億 USD | 1.58億 USD | 1.53億 USD |
| 受取利息 | 2878.9万 USD | 2631.5万 USD | 1489.8万 USD | 406万 USD | 44.3万 USD |
| 減価償却費と償却費 | 128万 USD | 296.3万 USD | 331.2万 USD | 336.9万 USD | 277.5万 USD |
| 営業利益 | −1.58億 USD | 2.53億 USD | −9365.2万 USD | −1.31億 USD | −1.26億 USD |
| 純利益 | −1.3億 USD | 2.75億 USD | −7895.5万 USD | −1.27億 USD | −1.26億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$176.29
上昇余地（22.65%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI3.03億0.01%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM2.27億0.29%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB2.19億0.12%1853億 USD0.03%$289.48+0.64%
State Street SPDR S&P Biotech ETFXBI1.44億1.46%98.74億 USD0.35%$153.77+3.00%
Vanguard Morningstar Small-Cap Growth ETFVBK1.25億0.27%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF1.04億0.11%954億 USD0.05%$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM8319.16万0.53%158.4億 USD0.03%$53.45+0.17%
Invesco S&P SmallCap Momentum ETFXSMO8229.91万2.87%28.69億 USD0.35%$81.75+0.57%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMInvesco S&P SmallCap Momentum ETFXSMOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
